Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FBIO Fortress Biotech	$1.95 -1.0%	$1.85	$1.33 ▼ $2.89	$57.51M	1.75	412,478 shs	197,218 shs
FLXN Flexion Therapeutics	$24.99 +0.3%	$9.20	$4.30 ▼ $13.66	$1.26B	1.53	1.18 million shs	N/A
MDVL MedAvail		$3.31	$1.31 ▼ $20.89	$2.91M	0.76	261,432 shs	245,100 shs
URGN Urogen Pharma	$15.38 +7.2%	$10.18	$3.42 ▼ $17.27	$711.89M	1.02	1.10 million shs	1.44 million shs
XOMA XOMA Royalty	$26.72 +0.4%	$25.75	$18.35 ▼ $35.00	$315.75M	0.93	36,286 shs	8,455 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FBIO Fortress Biotech	+1.55%	-1.01%	+7.07%	+28.76%	-2.96%
FLXN Flexion Therapeutics	-0.26%	-0.10%	+173.24%	+173.24%	+173.24%
MDVL MedAvail	0.00%	0.00%	0.00%	0.00%	0.00%
URGN Urogen Pharma	+2.14%	+3.84%	0.00%	+48.29%	-16.72%
XOMA XOMA Royalty	+1.33%	-3.97%	+9.64%	+25.64%	-1.44%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
FBIO Fortress Biotech	2.5371 of 5 stars	3.5	1.0	0.0	0.0	2.2	3.3	0.6
FLXN Flexion Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MDVL MedAvail	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
URGN Urogen Pharma	4.3331 of 5 stars	4.5	2.0	0.0	4.5	1.3	2.5	0.0
XOMA XOMA Royalty	3.8058 of 5 stars	3.5	2.0	0.0	3.0	1.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FBIO Fortress Biotech	3.00	Buy	$21.00	976.92% Upside
FLXN Flexion Therapeutics	0.00	N/A	N/A	N/A
MDVL MedAvail	0.00	N/A	N/A	N/A
URGN Urogen Pharma	3.00	Buy	$32.86	113.69% Upside
XOMA XOMA Royalty	3.00	Buy	$69.50	160.15% Upside

Current Analyst Ratings Breakdown

Latest FBIO, URGN, FLXN, XOMA, and MDVL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$50.00
7/7/2025	URGN Urogen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/16/2025	URGN Urogen Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$50.00
6/13/2025	URGN Urogen Pharma	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Neutral ➝ Neutral	$16.00
6/13/2025	URGN Urogen Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Buy	$31.00
6/13/2025	URGN Urogen Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/13/2025	URGN Urogen Pharma	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Outperform ➝ Sector Outperform	$23.00 ➝ $47.00
6/13/2025	URGN Urogen Pharma	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $30.00
6/12/2025	URGN Urogen Pharma	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
6/3/2025	URGN Urogen Pharma	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$36.00 ➝ $10.00
5/28/2025	XOMA XOMA Royalty	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$104.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FBIO Fortress Biotech	$57.67M	1.00	N/A	N/A	($0.06) per share	-32.50
FLXN Flexion Therapeutics	$85.55M	14.70	N/A	N/A	($0.34) per share	-73.49
MDVL MedAvail	$43.33M	0.00	N/A	N/A	$13.01 per share	0.00
URGN Urogen Pharma	$90.40M	7.84	N/A	N/A	($0.21) per share	-73.22
XOMA XOMA Royalty	$13.05M	24.50	N/A	N/A	$6.95 per share	3.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FBIO Fortress Biotech	-$46M	-$2.23	N/A	N/A	N/A	-71.24%	-4,712.53%	-27.67%	8/12/2025 (Estimated)
FLXN Flexion Therapeutics	-$113.71M	-$2.01	N/A	N/A	N/A	-100.32%	N/A	-44.26%	N/A
MDVL MedAvail	-$47.62M	-$28.72	N/A	N/A	N/A	-192.97%	-218.10%	-103.45%	N/A
URGN Urogen Pharma	-$126.87M	-$3.18	N/A	N/A	N/A	-150.68%	-97,487.15%	-49.57%	8/12/2025 (Estimated)
XOMA XOMA Royalty	-$13.82M	-$1.15	N/A	N/A	N/A	-13.04%	-12.43%	-4.85%	8/12/2025 (Estimated)

Latest FBIO, URGN, FLXN, XOMA, and MDVL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	FBIO Fortress Biotech	-$0.31	N/A	N/A	N/A	$14.53 million	N/A
8/12/2025	Q2 2025	URGN Urogen Pharma	-$0.85	N/A	N/A	N/A	$23.06 million	N/A
8/12/2025	Q2 2025	XOMA XOMA Royalty	-$0.12	N/A	N/A	N/A	$9.39 million	N/A
5/13/2025	Q1 2025	XOMA XOMA Royalty	-$0.26	$0.06	+$0.32	$0.06	$6.75 million	$15.91 million
5/12/2025	Q1 2025	URGN Urogen Pharma	-$0.83	-$0.92	-$0.09	-$0.92	$22.71 million	$20.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
FBIO Fortress Biotech	N/A	N/A	N/A	N/A	N/A
FLXN Flexion Therapeutics	N/A	N/A	N/A	N/A	N/A
MDVL MedAvail	N/A	N/A	N/A	N/A	N/A
URGN Urogen Pharma	N/A	N/A	N/A	N/A	N/A
XOMA XOMA Royalty	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FBIO Fortress Biotech	1.74	1.72	1.55
FLXN Flexion Therapeutics	N/A	4.38	4.05
MDVL MedAvail	N/A	N/A	N/A
URGN Urogen Pharma	N/A	5.65	5.47
XOMA XOMA Royalty	1.18	5.54	5.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FBIO Fortress Biotech	96.51%
FLXN Flexion Therapeutics	90.01%
MDVL MedAvail	N/A
URGN Urogen Pharma	91.29%
XOMA XOMA Royalty	95.92%

Insider Ownership

Company	Insider Ownership
FBIO Fortress Biotech	27.90%
FLXN Flexion Therapeutics	9.13%
MDVL MedAvail	1.50%
URGN Urogen Pharma	5.10%
XOMA XOMA Royalty	9.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FBIO Fortress Biotech	170	29.57 million	21.32 million	Optionable
FLXN Flexion Therapeutics	257	50.32 million	45.73 million	No Data
MDVL MedAvail	279	1.61 million	1.59 million	No Data
URGN Urogen Pharma	200	46.11 million	43.76 million	Optionable
XOMA XOMA Royalty	10	11.97 million	10.88 million	Optionable

FBIO, URGN, FLXN, XOMA, and MDVL Headlines

Recent News About These Companies

Research non-profit to acquire embattled Essa in Xoma Royalty-backed deal

July 14 at 11:41 AM | fiercebiotech.comF

ESSA Pharma Inc. Announces Definitive Agreement to be Acquired by XenoTherapeutics, Inc., Backed by XOMA Royalty Corporation in All-Cash Transaction

July 14 at 8:00 AM | prnewswire.com

XOMA Royalty (NASDAQ:XOMA) Share Price Crosses Above 200 Day Moving Average - Here's Why

July 10, 2025 | marketbeat.com

Acuitas Investments LLC Trims Stake in XOMA Royalty Corporation (NASDAQ:XOMA)

July 2, 2025 | marketbeat.com

Top biotech deals in June 2025

July 2, 2025 | labiotech.euL

XOMA Royalty (NASDAQ:XOMA) Downgraded by Wall Street Zen to Hold

June 28, 2025 | marketbeat.com

XOMA Royalty to Buy Turnstone Biologics

June 27, 2025 | marketwatch.com

Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for ...

June 27, 2025 | gurufocus.com

Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for ...

June 27, 2025 | gurufocus.com

XOMA Royalty Corporation to Acquire Turnstone Biologics Corp. in Cash and CVR Merger Deal

June 27, 2025 | quiverquant.comQ

Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right

June 27, 2025 | globenewswire.com

XOMA Royalty (XOMA) Moves 9.0% Higher: Will This Strength Last?

June 24, 2025 | zacks.com

XOMA Royalty (NASDAQ:XOMA) Stock Crosses Above 200 Day Moving Average - Should You Sell?

June 24, 2025 | marketbeat.com

XOMA Preferred Shares Series A declares $0.539 dividend

June 18, 2025 | seekingalpha.com

XOMA Corp - 8.375% DP PFD B declares $0.5234 dividend

June 18, 2025 | seekingalpha.com

XOMA Royalty Declares Quarterly Preferred Stock Dividends

June 18, 2025 | investing.com

XOMA Royalty Declares Quarterly Preferred Stock Dividends

June 18, 2025 | globenewswire.com

Positive Outlook for Xoma: Strategic Positioning and Pricing Dynamics Drive Buy Rating

May 29, 2025 | tipranks.com

XOMA boosts stake in anti-CD38 antibody with $30 million deal

May 28, 2025 | thepharmaletter.comT

XOMA Royalty Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

May 28, 2025 | benzinga.com

XOMA’s Strategic Expansion and Mezagitamab’s Market Potential Drive Buy Rating

May 28, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBIO, URGN, FLXN, XOMA, and MDVL Company Descriptions

Fortress Biotech NASDAQ:FBIO

$1.95 -0.02 (-1.02%)

As of 03:05 PM Eastern

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

Flexion Therapeutics NASDAQ:FLXN

Flexion Therapeutics, Inc. operates as a biopharmaceutical company, which engages in the development and commercialization of novel and local therapies. It specializes in the treatment of patients with musculoskeletal conditions including osteoarthritis. It offers products under the Zilretta brand, an extended-release corticosteroid approved to manage osteoarthritis knee pain. The company was founded by Michael D. Clayman and Neil Bodick on November 5, 2007 and is headquartered in Burlington, MA.

MedAvail NASDAQ:MDVL

MedAvail Holdings, Inc., a technology-enabled retail pharmacy technology and services company, develops and commercializes self-service pharmacy, mobile application, and kiosk solutions in the United States and Canada. It offers a pharmacy technology solution, including the MedAvail MedCenter, which enables on-site pharmacy in medical clinics, retail store locations, employer sites with and without onsite clinics, and other location where onsite prescription dispensing is desired, as well as establishes an audio-visual connection to a live pharmacist enabling prescription drug dispensing to occur directly to a patient with real-time supervision by a pharmacist. The company is headquartered in Phoenix, Arizona. On February 2, 2024, MedAvail Holdings, Inc along with its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the U.S. Bankruptcy Court for the District of Delaware.

Urogen Pharma NASDAQ:URGN

$15.38 +1.04 (+7.22%)

As of 03:05 PM Eastern

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.

XOMA Royalty NASDAQ:XOMA

$26.72 +0.11 (+0.39%)

As of 03:05 PM Eastern

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets. It has a portfolio with various assets. XOMA Corporation was incorporated in 1981 and is headquartered in Emeryville, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time